Dataset from A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of Delamanid (OPC-67683) Administered Orally as 200 mg Total Daily Dose for Six Months in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00008649
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this trial is to determine whether delamanid is effective in the treatment of
multidrug-resistant tuberculosis (MDR TB) in combination with other MDR TB medications during
6 months of treatment.
创建时间：
2025-04-17
